1. Home
  2. FEMY vs PIII Comparison

FEMY vs PIII Comparison

Compare FEMY & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FEMY
  • PIII
  • Stock Information
  • Founded
  • FEMY 2004
  • PIII 2015
  • Country
  • FEMY United States
  • PIII United States
  • Employees
  • FEMY 71
  • PIII N/A
  • Industry
  • FEMY Medical/Dental Instruments
  • PIII Medical/Nursing Services
  • Sector
  • FEMY Health Care
  • PIII Health Care
  • Exchange
  • FEMY Nasdaq
  • PIII Nasdaq
  • Market Cap
  • FEMY 23.1M
  • PIII 20.8M
  • IPO Year
  • FEMY 2021
  • PIII N/A
  • Fundamental
  • Price
  • FEMY $0.71
  • PIII $6.78
  • Analyst Decision
  • FEMY Strong Buy
  • PIII Buy
  • Analyst Count
  • FEMY 3
  • PIII 2
  • Target Price
  • FEMY $7.33
  • PIII $16.25
  • AVG Volume (30 Days)
  • FEMY 238.0K
  • PIII 12.0K
  • Earning Date
  • FEMY 08-08-2025
  • PIII 08-14-2025
  • Dividend Yield
  • FEMY N/A
  • PIII N/A
  • EPS Growth
  • FEMY N/A
  • PIII N/A
  • EPS
  • FEMY N/A
  • PIII N/A
  • Revenue
  • FEMY $1,887,016.00
  • PIII $1,461,823,000.00
  • Revenue This Year
  • FEMY $283.83
  • PIII N/A
  • Revenue Next Year
  • FEMY $161.03
  • PIII $7.92
  • P/E Ratio
  • FEMY N/A
  • PIII N/A
  • Revenue Growth
  • FEMY 98.61
  • PIII 4.20
  • 52 Week Low
  • FEMY $0.69
  • PIII $5.80
  • 52 Week High
  • FEMY $1.80
  • PIII $30.50
  • Technical
  • Relative Strength Index (RSI)
  • FEMY 34.99
  • PIII 48.91
  • Support Level
  • FEMY $0.72
  • PIII $6.42
  • Resistance Level
  • FEMY $1.00
  • PIII $7.11
  • Average True Range (ATR)
  • FEMY 0.06
  • PIII 0.55
  • MACD
  • FEMY -0.01
  • PIII -0.03
  • Stochastic Oscillator
  • FEMY 0.89
  • PIII 45.35

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

Share on Social Networks: